Abstract
Cisplatin and L-PAM are DNA-crosslinking anticancer agents which have not been systematically studied for vesicant potential. Mitoxantrone is a new active anthracene-based, DNA intercalator which is undergoing widespread clinical testing for antitumor efficacy in man. These three agents were tested for vesicant activity in dehaired BALB/c mice given ID injections equivalent to human clinical doses. Neither cisplatin (up to 150 mg/m2) nor L-PAM (up to 71 mg/m2) produced any skin necrosis in the mice. The L-PAM solvent (acid/alcohol in propylene glycol) was ulcerogenic if injected undiluted. Mitoxantrone (up to 14 mg/m2) was not ulcerogenic in the mice, although the skin site retained a blue drug discoloration for several weeks. It is concluded that in clinically relevant doses, cisplatin, L-PAM, and mitoxantrone are not vesicants.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 91-94 |
| Number of pages | 4 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1986 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Oncology
- Cancer Research
Cite this
Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. / Dorr, Robert T; Alberts, David S; Soble, Michelle.
In: Cancer Chemotherapy and Pharmacology, Vol. 16, No. 2, 03.1986, p. 91-94.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone
AU - Dorr, Robert T
AU - Alberts, David S
AU - Soble, Michelle
PY - 1986/3
Y1 - 1986/3
N2 - Cisplatin and L-PAM are DNA-crosslinking anticancer agents which have not been systematically studied for vesicant potential. Mitoxantrone is a new active anthracene-based, DNA intercalator which is undergoing widespread clinical testing for antitumor efficacy in man. These three agents were tested for vesicant activity in dehaired BALB/c mice given ID injections equivalent to human clinical doses. Neither cisplatin (up to 150 mg/m2) nor L-PAM (up to 71 mg/m2) produced any skin necrosis in the mice. The L-PAM solvent (acid/alcohol in propylene glycol) was ulcerogenic if injected undiluted. Mitoxantrone (up to 14 mg/m2) was not ulcerogenic in the mice, although the skin site retained a blue drug discoloration for several weeks. It is concluded that in clinically relevant doses, cisplatin, L-PAM, and mitoxantrone are not vesicants.
AB - Cisplatin and L-PAM are DNA-crosslinking anticancer agents which have not been systematically studied for vesicant potential. Mitoxantrone is a new active anthracene-based, DNA intercalator which is undergoing widespread clinical testing for antitumor efficacy in man. These three agents were tested for vesicant activity in dehaired BALB/c mice given ID injections equivalent to human clinical doses. Neither cisplatin (up to 150 mg/m2) nor L-PAM (up to 71 mg/m2) produced any skin necrosis in the mice. The L-PAM solvent (acid/alcohol in propylene glycol) was ulcerogenic if injected undiluted. Mitoxantrone (up to 14 mg/m2) was not ulcerogenic in the mice, although the skin site retained a blue drug discoloration for several weeks. It is concluded that in clinically relevant doses, cisplatin, L-PAM, and mitoxantrone are not vesicants.
UR - http://www.scopus.com/inward/record.url?scp=0022619626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022619626&partnerID=8YFLogxK
U2 - 10.1007/BF00256155
DO - 10.1007/BF00256155
M3 - Article
C2 - 3948308
AN - SCOPUS:0022619626
VL - 16
SP - 91
EP - 94
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 2
ER -